Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.72 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28433352 | 0.94 | YTHDC1 (0.74) | YTHDC1CTSLNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16549246 | 0.90 | YTHDC1 (0.69) | YTHDC1NPC1RAB9ASMN1; SMN2ADORA3 | |
| SCHEMBL16549233 | 0.89 | YTHDC1 (0.68) | YTHDC1NPC1RAB9ASMN1; SMN2ADORA3 | |
| SCHEMBL17902915 | 0.88 | YTHDC1 (0.71) | YTHDC1NPC1RAB9ASMN1; SMN2ADORA3 | |
| SCHEMBL17929775 | 0.87 | YTHDC1 (0.70) | YTHDC1NPC1RAB9ASMN1; SMN2ADORA3 | |
| SCHEMBL6820593 | 0.85 | CTSL (0.66) | YTHDC1CTSLADORA3ADORA1FLT3 | |
| SCHEMBL28426649 | 0.85 | YTHDC1 (0.67) | YTHDC1NPC1RAB9ASMN1; SMN2ADORA3 | |
| SCHEMBL17902904 | 0.84 | YTHDC1 (0.72) | YTHDC1NPC1RAB9ASMN1; SMN2ADORA3 | |
| SCHEMBL19049986 | 0.84 | YTHDC1 (1.00) | YTHDC1NPC1RAB9ASMN1; SMN2ADORA3 | |
| SCHEMBL5695023 | 0.83 | YTHDC1 (0.65) | YTHDC1NPC1RAB9ASMN1; SMN2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180117048-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117048-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | IFNG, IFNAR1, IRF3 | YTHDC1 1280/4885CTSL 518/4885NPC1 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.